Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer–Associated CA125 from Benign Sources

Gidwani, Kamlesh; Nadeem, Nimrah; Huhtinen, Kaisa; Kekki, Henna; Heinosalo, Taija; Hynninen, Johanna; Perheentupa, Antti; Poutanen, Matti; Carpén, Olli; Pettersson, Kim; Lamminmäki, Urpo

doi:10.1373/jalm.2018.028266

Cited by 13 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the healthy women, 40 serum samples were tested (Supplementary Table 1 ). We have evaluated the same cohort earlier (healthy, endometriosis, and EOC) with the plate-based CA125-STn assay developed 21 , 29 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125

et al. 2020

Self Cite

View full text Add to dashboard Cite

Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve differential diagnosis of the disease. Here we describe the development of a quantitative lateral flow immunoassay (LFIA) of aberrantly glycosylated CA125 which is widely superior to the conventional CA125 immunoassay (CA125IA). With a 30 min read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35–200 U/mL), in comparison to 16% sensitivity with the CA125IA. We envision the clinical use of the developed LFIA to be based on the substantially enhanced disease specificity against the many benign conditions confounding the diagnostic evaluation and against other cancers.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Therefore, glycan biomarkers of EOC could be a viable differential diagnostic tool. Gidwani et al 20 , 21 recently demonstrated a CA125 glycovariant-based assay utilizing fluorescent-europium nanoparticles, which improves discrimination of EOC from benign endometriosis disease compared to the conventional immunoassays.…”

Section: Introductionmentioning

confidence: 99%

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Extracellular vesicles (EVs) have been widely investigated in recent years, and emerging data suggest that cancer-derived EVs are strongly glycosylated, being rich in specific glycoconjugate [ 21 ]. In this study, we report on fluorescence europium chelate dyed-nanoparticles (Eu-NP)-based TRF assays to demonstrate the presence of specific proteins and glycans on the surface of EVs in CRC cell culture spend medium and further clinical evaluation of promising candidates in clinical serum samples–We have previously utilized the lectin-NP-based platform successfully to explore the glycosylation of serum glycoproteins CA125 (CA125 MGL ) and CA15-3 (CA15-3 WGA) in ovarian and breast cancer patients’ samples [ 31 , 32 ]. More recently, our group developed NP-based TRF assay for analysis and characterization of EVs and identification of disease-specific markers on the surface of patient-derived urinary EVs [ 30 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Nanoparticle-Aided Detection of Colorectal Cancer-Associated Glycoconjugates of Extracellular Vesicles in Human Serum

Vinod

Mahran

Routila

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are found in all biological fluids, providing potential for the identification of disease biomarkers such as colorectal cancer (CRC). EVs are heavily glycosylated with specific glycoconjugates such as tetraspanins, integrins, and mucins, reflecting the characteristics of the original cell offering valuable targets for detection of CRC. We report here on europium-nanoparticle (EuNP)-based assay to detect and characterize different surface glycoconjugates of EVs without extensive purification steps from five different CRC and the HEK 293 cell lines. The promising EVs candidates from cell culture were clinically evaluated on small panel of serum samples including early-stage (n = 11) and late-stage (n = 11) CRC patients, benign condition (n = 11), and healthy control (n = 10). The majority of CRC cell lines expressed tetraspanin sub-population and glycovariants of integrins and conventional tumor markers. The subpopulation of CD151 having CD63 expression (CD151CD63) was significantly (p = 0.001) elevated in early-stage CRC (8 out of 11) without detecting any benign and late-stage samples, while conventional CEA detected mostly late-stage CRC (p = 0.045) and with only four early-stage cases. The other glycovariant assays such as CEACon-A, CA125WGA, CA 19.9Ma696, and CA 19.9Con-A further provided some complementation to the CD151CD63 assay. These results indicate the potential application of CD151CD63 assay for early detection of CRC patients in human serum.

show abstract

“…The serum CA125 glycoform measurement with in-house time resolved fluorometry (TRF) CA125-MGL and CA125-STn immunoassays were performed in an identical manner to as described before [30,31]. In short, biotinylated capture Ov185 monoclonal antibody or Ov185 F (ab')2 (50 ng/30 μl /well) were immobilized to streptavidin-coated low-fluorescence microtiter wells (Kaivogen Oy, Turku, Finland) in the assay buffer.…”

Section: Sample Collection and Biomarker Analysesmentioning

confidence: 99%

A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Salminen

Nadeem

Jain

et al. 2020

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer–Associated CA125 from Benign Sources

Cited by 13 publications

References 37 publications

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125

Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125

Nanoparticle-Aided Detection of Colorectal Cancer-Associated Glycoconjugates of Extracellular Vesicles in Human Serum

A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Contact Info

Product

Resources

About